TRIAMCINOLONE INJ,SUSP
Clinical Criteria Summary
Indication & Patient Population
- • Treatment of macular edema associated with uveitis (UME) / non-infectious uveitis (anterior, intermediate, posterior, or panuveitis).
- • Patients with central subfield thickness (CST) of 300 µm or more measured by optical coherence tomography.
- • Patients who have had an inadequate response or clinically significant adverse events to periocular or intravitreal triamcinolone injection, or have contraindications to those therapies.
- • Steroid-responsive patients, particularly those unable to tolerate an additional increase in intraocular pressure (IOP).
Dosing & Administration
- • Suprachoroidal injection via proprietary SCS Microinjector.
- • Dose: 4 mg of triamcinolone acetonide (0.1 mL) per administration.
- • Single-dose package intended for use in only one eye.
- • Administered at baseline and week 12.
- • Office-setting procedure requiring minimal training for the retinal specialist.
Contraindications & Exclusions
- • Ocular or periocular infection.
- • Hypersensitivity to triamcinolone or its components.
- • Active ocular disease or infection in the study eye other than uveitis.
- • Uncontrolled glaucoma.
- • IOP greater than 22 mmHg.
- • Active ocular herpes simplex.
Safety & Monitoring Considerations
- • Use of corticosteroids may produce cataracts, increased intraocular pressure, and glaucoma.
- • Use of corticosteroids may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses.
- • Corticosteroids should be used cautiously in patients with a history of ocular herpes simplex.
- • Corticosteroids should not be used in patients with active ocular herpes simplex.
Practice & Specialist Restrictions
- • Use restricted to retina and uveitis specialists.